3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
8
Venous Thrombosis
4
Neoplasms
4
Pulmonary Embolism
2
Lung Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Thrombosis
1
Thromboembolism
1
Thrombocytopenia
1
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Epoetin Alfa
6
olaparib
5
pegfilgrastim
3
Filgrastim
3
Carboplatin
3
pembrolizumab
2
pegylated granulocyte colony-stimulating factor
2
palbociclib
2
abemaciclib
2
Tretinoin
2
venetoclax
1
trametinib
1
talazoparib
1
stinging nettle lectin
1
ruxolitinib
1
ribociclib
1
regorafenib
1
ponatinib
1
pertuzumab
1
peppermint oil
1
neratinib
1
lorlatinib
1
lenvatinib
1
idelalisib
1
fludarabine phosphate
1
enzalutamide
1
entrectinib
1
enasidenib
1
durvalumab
1
dehydroftorafur
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Tinzaparin
×
Classical hematology
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled